London-based Punto Health has raised €2.3 million in seed funding co-led by Shilling VC and Plus Partners, with participation from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest. The funding will be used to accelerate product development and commercial expansion across the UK and Spain.
Punto Health was founded in 2023 by engineers Anna Muñoz-Farré and Jack Eckersley. The company develops AI-powered tools for early detection and personalized support in dementia and cognitive decline.
The platform connects patients, carers, and clinicians across three products. PuntoTest is an AI-powered, speech-based digital test for assessing cognitive impairment. PuntoCare is a companion app that provides care plans, cognitive stimulation exercises, nutrition advice, symptom tracking, and wellness support. PuntoClinic is a clinician-facing dashboard that aggregates patient-reported outcomes and biomarker data.
In Spain, PuntoTest has been tested across ten pharmacies in Barcelona involving more than 1,500 participants aged 50 and above. The platform is being piloted at North London NHS Foundation Trust, NHS Oxleas Foundation Trust, and hospitals in Barcelona. Punto Health supports more than 200 users aged 60 to 90 who have completed over 30,000 activities.
Women are disproportionately affected by dementia. Since women generally live longer than men and age is the biggest risk factor, more women develop dementia. The drop in oestrogen during menopause may leave women’s brains more vulnerable, as oestrogen has neuroprotective effects. Women also provide about two-thirds of unpaid care for people with dementia.
The platform is co-designed and clinically validated in partnership with Ace Alzheimer Centre Barcelona. This seed round builds on a €718,500 pre-seed investment.
